是否应扩大乙型肝炎抗病毒治疗的适应症，将免疫耐受患者、非活动性携带者或处于 "灰色地带 "的患者包括在内？

{"title":"是否应扩大乙型肝炎抗病毒治疗的适应症，将免疫耐受患者、非活动性携带者或处于 \"灰色地带 \"的患者包括在内？","authors":"Yen-Chun Liu, W. Jeng","doi":"10.1007/s11901-024-00635-w","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":10857,"journal":{"name":"Current Hepatology Reports","volume":"124 ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?\",\"authors\":\"Yen-Chun Liu, W. Jeng\",\"doi\":\"10.1007/s11901-024-00635-w\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":10857,\"journal\":{\"name\":\"Current Hepatology Reports\",\"volume\":\"124 \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Hepatology Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s11901-024-00635-w\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Hepatology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11901-024-00635-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}